A week After Volunteer Fell Ill, Johnson & Johnson Set to Resume Covid Vaccine Trial in US
Small bottles labeled with a "Vaccine COVID-19" sticker and a medical syringe. (Reuters)
J&J said it was "planning to resume recruitment" for the phase 3 trial, which began in late September and should ultimately include 60,000 participants. "After a thorough evaluation of a serious medical event experienced by one study participant, no clear cause has been identified," the group said in a statement.
"The company has found no evidence that the vaccine candidate caused the event."